Since IL-6 is a major growth and survival factor in MM cells [122,123], and adherence of MM cells to BMSCs confers resistance to conventional drug-induced apoptosis, specific blockade of NF-κB signaling in BMSCs represents a novel therapeutic strategy in MM (Figure 2). Here, NFKB1 is linked to Miyoshi myopathy.